Last week, at the European Meeting of the International Society of Medical Publication Professionals, pharmaceutical firm Ipsen announced a breakthrough dramatically affecting doctors and patients alike.

This important research advancement did not occur in any laboratory – it emerged after close examination of the drug company’s communications policy.

In the lab, Ipsen concentrates its research in three key therapeutic areas: oncology, rare disease and neuroscience. At the writing desk, it is also a leader in making that research widely available. Since 2019, Ipsen has committed to publishing its research exclusively with Open Access journals.

Click below to listen to the latest episode of the Velocity of Content podcast

Plain Language Means Better Science

Now, Ipsen has become the first pharmaceutical company to commit to publishing, as a minimum, a 250-word plain language summary alongside all company-sponsored journal publications that include data from human studies. This commitment will apply to articles published from July 2022.

We devote this program to the Ipsen announcement and what it means for patients, publishers and physicians. Featured guests are Dr. Oleksandr Gorbenko, Ipsen global patient-centricity director; Adeline Rosenberg, medical writer, Oxford PharmaGenesis; and Joanne Walker, head of publishing solutions, the Future Science Group.


Author: Christopher Kenneally

Christopher Kenneally hosts CCC's Velocity of Content podcast series, which debuted in 2006 and is the longest continuously running podcast covering the publishing industry. As CCC's Senior Director, Marketing, he is responsible for organizing and hosting programs that address the business needs of all stakeholders in publishing and research. His reporting has appeared in the New York Times, Boston Globe, Los Angeles Times, The Independent (London), WBUR-FM, NPR, and WGBH-TV.
Don't Miss a Post

Subscribe to the award-winning
Velocity of Content blog